Baveno VII–renewing consensus in portal hypertension
…, SG Rodrigues, J Gracia-Sancho, G Han… - Journal of …, 2022 - Elsevier
To expand on the work of previous meetings, a virtual Baveno VII workshop was organised
for October 2021. Among patients with compensated cirrhosis or compensated advanced …
for October 2021. Among patients with compensated cirrhosis or compensated advanced …
Gold nanoparticles in delivery applications
Gold nanoparticles (AuNPs) provide non-toxic carriers for drug and gene delivery applications.
With these systems, the gold core imparts stability to the assembly, while the monolayer …
With these systems, the gold core imparts stability to the assembly, while the monolayer …
[HTML][HTML] Recent development of two-dimensional transition metal dichalcogenides and their applications
… specific capacities of 372 mAh/g and measured capacities of 150 mAh/g, which are not suitable
… a high theoretical capacity of ∼670 mAh/g and large van der Waal gaps between MoS 2 …
… a high theoretical capacity of ∼670 mAh/g and large van der Waal gaps between MoS 2 …
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 …
…, MA LeBerre, A Baumhauer, G Meinhardt, G Han - The Lancet, 2017 - thelancet.com
Background There are no systemic treatments for patients with hepatocellular carcinoma (HCC)
whose disease progresses during sorafenib treatment. We aimed to assess the efficacy …
whose disease progresses during sorafenib treatment. We aimed to assess the efficacy …
Non-fullerene acceptors with branched side chains and improved molecular packing to exceed 18% efficiency in organic solar cells
… The ZnO precursor was prepared by dissolving 1 g zinc acetate dihydrate and 280 µl
ethanolamine in 20 ml of 2-methoxyethanol under stirring overnight for the hydrolysis reaction. The …
ethanolamine in 20 ml of 2-methoxyethanol under stirring overnight for the hydrolysis reaction. The …
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
…, K Ikeda, F Piscaglia, A Baron, JW Park, G Han… - The Lancet, 2018 - thelancet.com
Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …
B cells and tertiary lymphoid structures promote immunotherapy response
… level log 2 (TPM+ 1 ) > 2 in either tested groups, G 1 and G 2 . Then, for each gene i, we
count the number of cells in G 1 and G 2 that express it with an expression level log 2 (TPM + 1) …
count the number of cells in G 1 and G 2 that express it with an expression level log 2 (TPM + 1) …
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
…, X Wang, DY Luo, H Wang, X Yang, Y Li, G Han… - Science, 2020 - science.org
… Substantial viral RNAs (10 8.32 copies/g) were readily detected after a single passage, …
Subsequently, the viral RNA copies in the lung approached 10 10.68 RNA copies/g at passage 3 …
Subsequently, the viral RNA copies in the lung approached 10 10.68 RNA copies/g at passage 3 …
9-Fluorenylmethoxycarbonyl amino-protecting group
LA Carpino, GY Han - The Journal of Organic Chemistry, 1972 - ACS Publications
… 39 g (0.20 mol) of xanthone in 500 ml of warm benzene was … taken up in benzene and passed
through 600 g of Florisil. The … of 2.0 g of 9fluorenylmethyl hydrazodiformate and 0.332 g of …
through 600 g of Florisil. The … of 2.0 g of 9fluorenylmethyl hydrazodiformate and 0.332 g of …
[HTML][HTML] Tumor-associated macrophages and survival in classic Hodgkin's lymphoma
Background Despite advances in treatments for Hodgkin's lymphoma, about 20% of
patients still die from progressive disease. Current prognostic models predict the outcome of …
patients still die from progressive disease. Current prognostic models predict the outcome of …